These data correlate with the decreased Aβ deposits in the brains of treated AD mice, and they are in good agreement with evidence showing that plasma leptin concentration is negatively associated to Aβ levels due to a direct regulatory effect on the γ-secretase-mediated amyloidogenic pathway10. The gene discussed is LEP; the disease is Alzheimer disease.